Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Iclusig (ponatinib) Tablets REMS
Goals of the Iclusig (ponatinib) Tablets REMS Program
The goals of the Iclusig REMS are to:Inform prescribers of the indications for Iclusig which are limited to:• Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated• Treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL Limitations of use: Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML.Inform prescribers of the risks of arterial occlusion and venous thromboembolism associated with Iclusig treatment
• Communication Plan